Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 1/20 | 0.32 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27189757 | 0.83 | ALDH1A1 (0.34) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL10514286 | 0.80 | USP2 (0.36) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL19766610 | 0.79 | SMN1; SMN2 (0.43) | MAP2K2MAP2K1CYP1A2SMN1; SMN2 | |
| SCHEMBL16333961 | 0.78 | ALDH1A1 (0.31) | MAP2K2MAP2K1ALDH1A1 | |
| SCHEMBL1972942 | 0.77 | SLC6A2 (0.33) | USP2ALDH1A1LMNACYP1A2TSHR | |
| SCHEMBL321213 | 0.76 | ALDH1A1 (0.34) | ALDH1A1LMNA | |
| SCHEMBL21585780 | 0.74 | — | — | |
| SCHEMBL23120756 | 0.71 | — | — | |
| SCHEMBL1141357 | 0.70 | USP2 (0.43) | USP2SMN1; SMN2 | |
| SCHEMBL15689513 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126855-B1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTIONS | HOFFMANN LA ROCHE (CH) | 2024-04-24 | — | — | EP | disclosed |
| EP-4346898-A1 | METHODS FOR INHIBITING RAS | Revolution Medicines, Inc. (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2023-06-01 | — | — | US | disclosed |
| WO-2023067354-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-04-27 | — | — | WO | disclosed |
| EP-4126855-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. Hoffmann-La Roche AG (CH) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021190727-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2021-09-30 | — | — | WO | disclosed |
| EP-3567030-A1 | QUINAZOLINE COMPOUND FOR EGFR INHIBITION | Medshine Discovery Inc. (CN) | 2019-11-13 | — | — | EP | disclosed |
| CN-110016020-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-07-16 | — | — | CN | disclosed |
| US-20190167679-A1 | sGC STIMULATORS | CYCLERION THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| CN-109384778-A | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 铁木医药有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109369635-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-108912111-A | compounds and pharmaceutical compositions | 铁木医药有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105408328-B | sGC stimulators | 铁木医药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| EP-2763990-B1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-02-22 | — | — | EP | disclosed |
| EP-2970243-A2 | SGC STIMULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014144100-A2 | SGC STIMULATORS | NAKAI TAKASHI (US) | 2014-09-18 | — | — | WO | disclosed |
| EP-2763990-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-08-13 | — | — | EP | disclosed |
| US-8658646-B2 | Pyrrolopyrazine kinase inhibitors | HOFFMANN-LAROCHE INC. (US) | 2014-02-25 | — | — | US | disclosed |
| WO-2013030138-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-07 | — | — | WO | disclosed |
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | HOFFMANN-LA ROCHE INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059834-A1 | PYRROLOPYRAZINE KINASE INHIBITORS | SYK, ZAP70, JAK1 | MAP2K2 435/4885MAP2K1 854/4885USP2 1510/4885 |
| US-20190167679-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | MAP2K2 3574/4885MAP2K1 3903/4885USP2 4302/4885 |
| US-20230167127-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | LTB4R, C5, C3AR1 | MAP2K2 4752/4885MAP2K1 4765/4885USP2 3512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.